SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 325 filers reported holding SAREPTA THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.84 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,171,393 | -64.5% | 92,158 | -66.5% | 0.01% | -62.5% |
| Q2 2023 | $31,483,724 | -73.2% | 274,919 | -67.7% | 0.03% | -74.6% |
| Q1 2023 | $117,394,910 | +53.0% | 851,737 | +43.8% | 0.13% | +50.0% |
| Q4 2022 | $76,743,366 | +6.3% | 592,247 | -9.3% | 0.08% | -2.3% |
| Q3 2022 | $72,166,000 | +268.2% | 652,861 | +149.7% | 0.09% | +273.9% |
| Q2 2022 | $19,601,000 | -13.9% | 261,483 | -10.3% | 0.02% | +9.5% |
| Q1 2022 | $22,765,000 | -29.4% | 291,408 | -18.6% | 0.02% | -22.2% |
| Q4 2021 | $32,246,000 | +296.2% | 358,095 | +306.9% | 0.03% | +285.7% |
| Q3 2021 | $8,138,000 | +369.0% | 87,998 | +294.3% | 0.01% | +600.0% |
| Q2 2021 | $1,735,000 | +71.3% | 22,318 | +64.3% | 0.00% | 0.0% |
| Q1 2021 | $1,013,000 | -82.0% | 13,586 | -58.9% | 0.00% | -83.3% |
| Q4 2020 | $5,636,000 | +106.4% | 33,060 | +70.0% | 0.01% | +200.0% |
| Q3 2020 | $2,731,000 | -78.1% | 19,452 | -75.0% | 0.00% | -86.7% |
| Q2 2020 | $12,453,000 | +3.4% | 77,668 | -36.9% | 0.02% | -21.1% |
| Q1 2020 | $12,048,000 | -30.7% | 123,160 | -8.6% | 0.02% | -5.0% |
| Q4 2019 | $17,385,000 | +62.2% | 134,732 | -5.3% | 0.02% | +42.9% |
| Q3 2019 | $10,718,000 | -49.8% | 142,300 | +1.3% | 0.01% | -48.1% |
| Q2 2019 | $21,348,000 | +85.8% | 140,495 | +45.7% | 0.03% | +92.9% |
| Q1 2019 | $11,490,000 | -42.0% | 96,400 | -46.9% | 0.01% | -48.1% |
| Q4 2018 | $19,796,000 | -52.9% | 181,400 | -30.3% | 0.03% | -46.0% |
| Q3 2018 | $42,014,000 | -37.6% | 260,131 | -48.9% | 0.05% | -42.5% |
| Q2 2018 | $67,352,000 | +1235.6% | 509,541 | +648.5% | 0.09% | +1142.9% |
| Q1 2018 | $5,043,000 | -65.4% | 68,077 | -74.0% | 0.01% | -63.2% |
| Q4 2017 | $14,582,000 | +66.8% | 262,075 | +36.0% | 0.02% | +46.2% |
| Q3 2017 | $8,740,000 | +103.7% | 192,691 | +51.4% | 0.01% | +62.5% |
| Q2 2017 | $4,290,000 | +56.9% | 127,254 | +37.8% | 0.01% | +60.0% |
| Q1 2017 | $2,734,000 | -21.4% | 92,378 | -27.2% | 0.01% | 0.0% |
| Q4 2016 | $3,480,000 | +41.7% | 126,884 | +217.2% | 0.01% | +25.0% |
| Q3 2016 | $2,456,000 | +221.9% | 40,000 | 0.0% | 0.00% | +300.0% |
| Q2 2016 | $763,000 | -95.1% | 40,000 | -94.9% | 0.00% | -96.3% |
| Q1 2016 | $15,459,000 | -43.1% | 791,942 | +12.5% | 0.03% | -34.1% |
| Q4 2015 | $27,150,000 | -20.3% | 703,740 | -33.7% | 0.04% | -18.0% |
| Q3 2015 | $34,086,000 | +116.9% | 1,061,532 | +105.6% | 0.05% | +117.4% |
| Q2 2015 | $15,714,000 | +360.3% | 516,376 | +100.9% | 0.02% | +360.0% |
| Q1 2015 | $3,414,000 | -30.9% | 257,088 | -24.7% | 0.01% | -16.7% |
| Q4 2014 | $4,939,000 | -70.8% | 341,294 | -57.5% | 0.01% | -72.7% |
| Q3 2014 | $16,927,000 | -57.7% | 802,260 | -40.2% | 0.02% | -59.3% |
| Q2 2014 | $39,982,000 | +158.5% | 1,342,112 | +108.5% | 0.05% | +145.5% |
| Q1 2014 | $15,467,000 | +20.3% | 643,643 | +1.9% | 0.02% | +22.2% |
| Q4 2013 | $12,862,000 | -50.3% | 631,413 | +15.3% | 0.02% | -56.1% |
| Q3 2013 | $25,857,000 | +68.9% | 547,455 | +36.1% | 0.04% | +41.4% |
| Q2 2013 | $15,310,000 | – | 402,375 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Casdin Capital, LLC | 1,010,330 | $122,472,203 | 13.56% |
| Finepoint Capital LP | 145,357 | $17,620,176 | 8.78% |
| Avoro Capital Advisors LLC | 4,025,000 | $487,910,500 | 7.61% |
| Saturn V Capital Management LP | 118,401 | $14,352,569 | 6.01% |
| Ghost Tree Capital, LLC | 150,000 | $18,183,000 | 5.98% |
| Ikarian Capital, LLC | 3,673 | $44,524,106 | 5.36% |
| ACUTA CAPITAL PARTNERS, LLC | 550 | $7,580,650 | 5.08% |
| Eagle Health Investments LP | 174,212 | $21,117,979 | 4.65% |
| Boxer Capital, LLC | 600,000 | $72,732,000 | 3.87% |
| GREAT POINT PARTNERS LLC | 165,200 | $20,025,544 | 3.65% |